0000899243-19-002666.txt : 20190205
0000899243-19-002666.hdr.sgml : 20190205
20190205175319
ACCESSION NUMBER: 0000899243-19-002666
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190201
FILED AS OF DATE: 20190205
DATE AS OF CHANGE: 20190205
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LOVE TED W
CENTRAL INDEX KEY: 0001188919
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37539
FILM NUMBER: 19569124
MAIL ADDRESS:
STREET 1: C/O GLOBAL BLOOD THERAPEUTICS, INC.
STREET 2: 400 EAST JAMIE COURT, SUITE 101
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc.
CENTRAL INDEX KEY: 0001629137
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 274825712
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 171 OYSTER POINT BLVD, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650741-7700
MAIL ADDRESS:
STREET 1: 171 OYSTER POINT BLVD, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-02-01
0
0001629137
Global Blood Therapeutics, Inc.
GBT
0001188919
LOVE TED W
C/O GLOBAL BLOOD THERAPEUTICS, INC.
171 OYSTER POINT BLVD., SUITE 300
SOUTH SAN FRANCISCO
CA
94080
1
1
0
0
See Remarks
Common Stock
2019-02-01
4
M
0
21813
A
1150788
D
Common Stock
2019-02-01
4
F
0
7814
48.44
D
1142974
D
Common Stock
2500
I
By Daughter
Common Stock
2500
I
By Daughter
Stock Option (Right to Buy)
48.44
2019-02-01
4
A
0
145000
0.00
A
2029-01-31
Common Stock
145000
145000
D
Restricted Stock Units
2019-02-01
4
A
0
90000
0.00
A
Common Stock
90000
90000
D
Restricted Stock Units
2019-02-01
4
M
0
12063
0.00
D
Common Stock
12063
48250
D
Restricted Stock Units
2019-02-01
4
M
0
9750
0.00
D
Common Stock
9750
58500
D
Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.
Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 21,813 shares of Common Stock underlying the Reporting Person's RSUs.
The shares of Common Stock underlying the option vest in 16 equal quarterly installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2017, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
Chief Executive Officer and President
/s/ Lesley Ann Calhoun, as Attorney-in-Fact
2019-02-05